The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.
Dermatology Clinical Trials Unit
Stephanie Farris, Clinical Research Coordinator
Phone: 314-747-8694 Fax: 314-362-6080
sefarris@wustl.edu
Justin Stout, Clinical Research Coordinator
Phone: 314-273-3737 Fax: 314-362-6080
justinjstout@wustl.edu
Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator
Phone: 314-362-8171 Fax: 314-362-6080
mtabacchi@wustl.edu
Milan Anadkat, MD, Director, Clinical Trials Unit
manadkat@wustl.edu
Currently Enrolling Trials
Dr. Milan Anadkat
Phase 1, Open-Label, Dose Escalation Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy Study of Topically Administered LUT014 (BRAF agonist) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions
A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 (IL-36R antagonist) in Subjects with Palmoplantar Pustulosis
Dr. Heather Jones
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum (Cannabanoid) in Dermatomyositis
Dr. Elizabeth Nieman
*Evaluation of the Pharmacokinetics and Safety of Upadacitinib (JAK-inhibitor) in Pediatric Subjects (ages 2-11) with Severe Atopic Dermatitis
Dr. Ann Martin
*A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream (JAK-inhibitor) Followed by an Extension Period in Participants with Vitiligo
Dr. Amy Musiek
Randomized, Double-Blind, Placebo-controlled study of Efficacy, Safety, and Tolerability of Serlopitant (neurokinin inhibitor) for the treatment of Chronic Pruritus of Unknown Origin
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL)